This trial is evaluating whether Docetaxel will improve 1 primary outcome and 6 secondary outcomes in patients with Metastatic Castration Resistant Prostate Cancer (CRPC). Measurement will happen over the course of 3 months.
This trial requires 100 total participants across 2 different treatment groups
This trial involves 2 different treatments. Docetaxel is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"The incidence and mortality rates per year were 0.1 and 0.2 per 1000 men in our state. The prevalence rate was higher, but still extremely low, averaging 0.065 man per 100,000 men. Over 100 million men are affected by prostate cancer in our population, and millions with this disease will develop and die without having ever been diagnosed." - Anonymous Online Contributor
"Men with benign prostate have larger prostate glands. The clinical relevance of prostate specific antigen screening and biopsy for all [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer)s and other forms of prostate cancer seems to be debatable. If we would take this into account, it is reasonable to recommend PSA screening for localized prostate cancers only in those men who have a higher risk of cancer, whereas in a general population (male) biopsy with PSA screening is debatable, too." - Anonymous Online Contributor
"The current paradigm for cure of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) is inappropriate. It is based on unrealistic models of cancer development and progression and is incompatible with the fact that the majority of prostate cancer patients do not live long enough to be cured." - Anonymous Online Contributor
"The risk of developing prostatic cancer is increased in men whose first degree relatives have had the disease. While not proven, there is suggestive evidence that hormonal factors are implicated in the development of prostate cancer." - Anonymous Online Contributor
"Treating PCa involves treatment options including hormonal therapy, radiation therapies and chemotherapy. Often, treatments are selected based on the PSA test results. A good relationship between the patient and his/her oncologist is necessary to achieve successful treatment results." - Anonymous Online Contributor
"Prostate-specific antigen level (PSA) is the most commonly used staging tool to determine the extent of disease. Prostate-specific antigen level is the standard for screening and follow-up of patients who have been diagnosed with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer)." - Anonymous Online Contributor
"To improve survival rate of PCa patients, we recommend a multimodality treatment plan including an active surveillance program and adjuvant and salvage therapy when needed." - Anonymous Online Contributor
"The average age of diagnosis in the current study is 60 years old which is consistent with other reported series. The average age of diagnosis for localized prostate cancer at diagnosis is 68 years old which is similar to other published series. An earlier age at diagnosis was related to an elevated risk for prostate cancer and lower rate of survival." - Anonymous Online Contributor
"The study suggests a role for common genetic predisposition in the development of malignant transformation in the prostate. On the grounds of this study, genetic counseling and the search for genes predisposing prostate carcinoma are warranted in young men with a first degree relative affected by prostate cancer and the search for a familial prostate cancer phenotype in apparently sporadic cases." - Anonymous Online Contributor
"There are many side effects and a large number of patients are discontinued after starting a docetaxel treatment. We did not find a way to predict which patients would suffer such side effects. We have to focus in the following side effects, but not all patients are afflicted by these side effects." - Anonymous Online Contributor
"The most common side effect of docetaxel is peripheral neuropathy, which may be due to a cumulative effect of taxanes. Peripheral neuropathy can be prevented by avoiding or mitigating other side effects of docetaxel. The side effects of docetaxel can be divided into general side effects, which are usually transient, and the hypersensitivity reactions which are seldom reported. In many cases hypersensitive reactions are triggered by the presence of docetaxel in the skin." - Anonymous Online Contributor
"The following factors should be considered when making informed decisions about participation in clinical trials of investigational investigational agents: comorbidity, prior therapy and baseline characteristics (PSA level, age, baseline grade, presence of PSA-doubling)." - Anonymous Online Contributor